{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:09:46Z","timestamp":1793045386571,"version":"4.5.0"},"reference-count":105,"publisher":"American Medical Association (AMA)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,5,20]]},"abstract":"<jats:sec id=\"ab-jrv250004-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive development of kidney cysts and is the most common inherited kidney disorder worldwide. ADPKD accounts for 5% to 10% of kidney failure in the US and Europe, and its prevalence in the US is 9.3 per 10\u202f000 individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250004-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the\n                      <jats:italic>PKD1<\/jats:italic>\n                      (78%) or\n                      <jats:italic>PKD2<\/jats:italic>\n                      (15%) genes. Most persons with ADPKD have an affected parent, but de novo disease is suggested in 10% to 25% of families. More than 90% of patients older than 35 years have hepatic cysts, which may cause abdominal discomfort and occasionally require medical or surgical intervention. Hypertension affects 70% to 80% of patients with ADPKD, and approximately 9% to 14% develop intracranial aneurysms, which have a rupture rate of 0.57 per 1000 patient-years. Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age. The severity of kidney disease can be quantified using the Mayo Imaging Classification (MIC), which stratifies patients based on total kidney volume adjusted for height and age and ranges from 1A to 1E. Patients with MIC 1C to MIC 1E have larger kidneys because of more rapid growth (6%-10% per year) compared with those with MIC 1A and 1B (1%-5% per year) and have earlier progression to kidney replacement therapy, which occurs at a mean age of 58.4 years for MIC 1C, 52.5 years for MIC 1D, and 43.4 years for MIC 1E. Optimal management of ADPKD includes systolic blood pressure lower than 120 mm Hg for most patients, but lower than 110\/75 mm Hg for patients with MIC 1C to 1E who have an estimated glomerular filtration rate (eGFR) greater than 60 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and are younger than 50 years, dietary sodium restriction (&amp;amp;lt;2000 mg\/d), weight management, and adequate hydration (&amp;amp;gt;2.5 L daily). The vasopressin type 2 receptor antagonist tolvaptan reduces the annual rate of eGFR decline by 0.98 to 1.27 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and is indicated for patients with MIC 1C to 1E or an eGFR decline greater than 3 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      per year to slow disease progression and delay the onset of kidney failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250004-3\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ADPKD is the most common genetic kidney disease worldwide and is characterized by progressive development of kidney cysts. Patients typically have hypertension and liver cysts, and 9% to 14% develop intracranial aneurysms. First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration. Tolvaptan reduces the rate of eGFR decline for those at high risk of rapid progression to kidney failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.0310","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T12:10:14Z","timestamp":1742818214000},"page":"1708","source":"Crossref","is-referenced-by-count":92,"title":["Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1001","volume":"333","author":[{"given":"Fouad T.","family":"Chebib","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hanna","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"},{"name":"Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"},{"name":"Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"},{"name":"Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"},{"name":"Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"jrv250004r1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials.","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"jrv250004r2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","article-title":"PKD2-related autosomal dominant polycystic kidney disease: prevalence, clinical presentation, mutation spectrum, and prognosis.","volume":"70","author":"Cornec-Le Gall","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"jrv250004r3","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing.","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"jrv250004r4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000494923","article-title":"Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015.","volume":"5","author":"Willey","year":"2019","journal-title":"Kidney diseases (Basel)"},{"issue":"1","key":"jrv250004r5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2215\/CJN.05900519","article-title":"Epidemiology of autosomal dominant polycystic kidney disease in Olmsted County.","volume":"15","author":"Suwabe","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"jrv250004r6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"jrv250004r7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1053\/j.ackd.2010.01.003","article-title":"Extrarenal manifestations of autosomal dominant polycystic kidney disease.","volume":"17","author":"Pirson","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"jrv250004r8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1474-4422(11)70109-0","article-title":"Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis.","volume":"10","author":"Vlak","year":"2011","journal-title":"Lancet Neurol"},{"issue":"10","key":"jrv250004r9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.ekir.2023.07.017","article-title":"Cardiovascular manifestations and management in ADPKD.","volume":"8","author":"Sagar","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"S2","key":"jrv250004r10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management and treatment of autosomal dominant polycystic kidney disease (ADPKD).","volume":"107","author":"KDIGO Workgroup","year":"2025","journal-title":"Kidney Int"},{"issue":"9","key":"jrv250004r11","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease.","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"jrv250004r12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ajhg.2021.11.016","article-title":"Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.","volume":"109","author":"Senum","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"5","key":"jrv250004r13","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1172\/JCI90129","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function.","volume":"127","author":"Besse","year":"2017","journal-title":"J Clin Invest"},{"issue":"5","key":"jrv250004r14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease.","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"11","key":"jrv250004r15","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 mutation carriers develop kidney and liver cysts.","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"jrv250004r16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.kint.2022.11.025","article-title":"Individuals heterozygous for ALG8 protein-truncating variants are at increased risk of a mild cystic kidney disease.","volume":"103","author":"Apple","year":"2023","journal-title":"Kidney Int"},{"issue":"8","key":"jrv250004r17","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.ajhg.2022.06.013","article-title":"Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis.","volume":"109","author":"Lemoine","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"5","key":"jrv250004r18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.kint.2023.07.021","article-title":"Certain heterozygous variants in the kinase domain of the serine\/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease.","volume":"104","author":"Claus","year":"2023","journal-title":"Kidney Int"},{"issue":"9","key":"jrv250004r19","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ng.2715","article-title":"Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease.","volume":"45","author":"Ma","year":"2013","journal-title":"Nat Genet"},{"issue":"10","key":"jrv250004r20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease.","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"jrv250004r21","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.","volume":"124","author":"Harris","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"jrv250004r22","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ki.1994.374","article-title":"Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.","volume":"46","author":"Barrett","year":"1994","journal-title":"Kidney Int"},{"issue":"5","key":"jrv250004r23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.","volume":"41","author":"Gabow","year":"1992","journal-title":"Kidney Int"},{"issue":"2","key":"jrv250004r24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1091\/mbc.e16-08-0597","article-title":"The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function.","volume":"28","author":"Padovano","year":"2017","journal-title":"Mol Biol Cell"},{"issue":"6","key":"jrv250004r25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease.","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"issue":"4","key":"jrv250004r26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential.","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"jrv250004r27","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice: autosomal dominant polycystic kidney disease.","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250004r28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1053\/j.ajkd.2011.12.022","article-title":"Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors.","volume":"59","author":"Rule","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"jrv250004r29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","article-title":"Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases.","volume":"31","author":"Van Keimpema","year":"2011","journal-title":"Liver Int"},{"issue":"1","key":"jrv250004r30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","article-title":"Liver involvement in early autosomal-dominant polycystic kidney disease.","volume":"13","author":"Hogan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"jrv250004r31","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/hep.1840110619","article-title":"Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease.","volume":"11","author":"Gabow","year":"1990","journal-title":"Hepatology"},{"issue":"5","key":"jrv250004r32","first-page":"1282","article-title":"Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease.","volume":"26","author":"Sherstha","year":"1997","journal-title":"Hepatology"},{"issue":"10","key":"jrv250004r33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease.","volume":"11","author":"Perrone","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"jrv250004r34","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/ndt\/gfac027","article-title":"Diagnosis and risk factors for intracranial aneurysms in autosomal polycystic kidney disease: a cross-sectional study from the Genkyst cohort.","volume":"37","author":"Lef\u00e8vre","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"jrv250004r35","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3174\/ajnr.A3456","article-title":"Intracranial aneurysms in autosomal dominant polycystic kidney disease.","volume":"34","author":"Niemczyk","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"jrv250004r36","doi-asserted-by":"publisher","first-page":"18056","DOI":"10.1038\/s41598-022-22884-9","article-title":"Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.","volume":"12","author":"Kataoka","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"jrv250004r37","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1681\/ASN.2016090938","article-title":"Polycystic kidney disease without an apparent family history.","volume":"28","author":"Iliuta","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"jrv250004r38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ekir.2023.02.1073","article-title":"OVERTURE: a worldwide, prospective, observational study of disease characteristics in patients with ADPKD.","volume":"8","author":"Perrone","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"4","key":"jrv250004r39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0272-6386(12)80922-X","article-title":"Renal stone disease in autosomal dominant polycystic kidney disease.","volume":"22","author":"Torres","year":"1993","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"jrv250004r40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"jrv250004r41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/jhep.2003.50006","article-title":"Clinical profile of autosomal dominant polycystic liver disease.","volume":"37","author":"Qian","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"jrv250004r42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/2050640617705577","article-title":"Impact of liver volume on polycystic liver disease-related symptoms and quality of life.","volume":"6","author":"Neijenhuis","year":"2018","journal-title":"United European Gastroenterol J"},{"issue":"5","key":"jrv250004r43","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MPA.0000000000001306","article-title":"Pancreatic cysts and intraductal papillary mucinous neoplasm in autosomal dominant polycystic kidney disease.","volume":"48","author":"McNicholas","year":"2019","journal-title":"Pancreas"},{"issue":"5","key":"jrv250004r44","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1378\/chest.07-2147","article-title":"Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis.","volume":"133","author":"Driscoll","year":"2008","journal-title":"Chest"},{"issue":"34","key":"jrv250004r45","doi-asserted-by":"publisher","first-page":"57594","DOI":"10.18632\/oncotarget.16338","article-title":"Risk of aortic aneurysm and dissection in patients with autosomal-dominant polycystic kidney disease: a nationwide population-based cohort study.","volume":"8","author":"Sung","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"jrv250004r46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1681\/ASN.V95837","article-title":"Coronary aneurysms in patients with autosomal dominant polycystic kidney disease.","volume":"9","author":"Hadimeri","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"jrv250004r47","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.ekir.2022.06.006","article-title":"Cardiovascular outcomes in kidney transplant recipients with ADPKD.","volume":"7","author":"Chedid","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"5","key":"jrv250004r48","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ekir.2017.05.014","article-title":"Autosomal dominant polycystic kidney patients may be predisposed to various cardiomyopathies.","volume":"2","author":"Chebib","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"6","key":"jrv250004r49","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2215\/CJN.01920507","article-title":"Increased occurrence of pericardial effusion in patients with autosomal dominant polycystic kidney disease.","volume":"2","author":"Qian","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"jrv250004r50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"jrv250004r51","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1681\/ASN.2014030297","article-title":"Imaging-based diagnosis of autosomal dominant polycystic kidney disease.","volume":"26","author":"Pei","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"10174","key":"jrv250004r52","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease.","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"jrv250004r53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"jrv250004r54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2024.05.010","article-title":"Advancing genetic testing in kidney diseases: report from a National Kidney Foundation Working Group.","volume":"84","author":"Franceschini","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"jrv250004r55","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"20","key":"jrv250004r56","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease.","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv250004r57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mayocpiqo.2022.12.005","article-title":"Changes in kidney and liver volumes in patients with autosomal dominant polycystic kidney disease before and after dialysis initiation.","volume":"7","author":"Suwabe","year":"2023","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"1","key":"jrv250004r58","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"jrv250004r59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD.","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"jrv250004r60","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease.","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"jrv250004r61","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2215\/CJN.14931121","article-title":"Total kidney volume measurements in ADPKD by 3D and ellipsoid ultrasound in comparison with magnetic resonance imaging.","volume":"17","author":"Akbari","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"jrv250004r62","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ekir.2020.12.016","article-title":"Characteristics of patients with end-stage kidney disease in ADPKD.","volume":"6","author":"Shukoor","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"3","key":"jrv250004r63","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease.","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"jrv250004r64","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1038\/s41598-022-24104-w","article-title":"Atypical polycystic kidney disease as defined by imaging.","volume":"13","author":"Iliuta","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"jrv250004r65","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2215\/CJN.0000000000000326","article-title":"Polycystic kidney disease diet: what is known and what is safe.","volume":"19","author":"Chebib","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"jrv250004r66","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan.","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"jrv250004r67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100639","article-title":"Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies.","volume":"5","author":"Chebib","year":"2023","journal-title":"Kidney Med"},{"issue":"8","key":"jrv250004r68","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","article-title":"Tolvaptan in ADPKD patients with very low kidney function.","volume":"6","author":"Torres","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"4S","key":"jrv250004r69","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"jrv250004r70","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.kint.2016.12.007","article-title":"Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease.","volume":"91","author":"Casteleijn","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"jrv250004r71","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"jrv250004r72","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100021","article-title":"Prescribed water intake in autosomal dominant polycystic kidney disease.","volume":"1","author":"Rangan","year":"2022","journal-title":"NEJM Evid"},{"issue":"24","key":"jrv250004r73","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease.","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250004r74","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study.","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"jrv250004r75","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv250004r76","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease.","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250004r77","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ekir.2022.02.009","article-title":"Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD.","volume":"7","author":"Zhou","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"8","key":"jrv250004r78","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","article-title":"Evaluating the impact of a risk evaluation and mitigation strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease.","volume":"15","author":"Estilo","year":"2022","journal-title":"Clin Kidney J"},{"issue":"1","key":"jrv250004r79","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13063-024-07952-x","article-title":"Hydrochlorothiazide versus placebo to protect polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial.","volume":"25","author":"Bais","year":"2024","journal-title":"Trials"},{"issue":"7","key":"jrv250004r80","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2215\/CJN.00840122","article-title":"Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States.","volume":"17","author":"McGill","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"jrv250004r81","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15216","article-title":"The effect of primary renal disease upon outcomes after renal transplant.","volume":"38","author":"Garland","year":"2024","journal-title":"Clin Transplant"},{"issue":"8","key":"jrv250004r82","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneph.2014.104","article-title":"Renal transplantation in autosomal dominant polycystic kidney disease.","volume":"10","author":"Kanaan","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"jrv250004r83","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s10620-007-0121-x","article-title":"Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts.","volume":"53","author":"van Keimpema","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"6","key":"jrv250004r84","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/hep.24036","article-title":"Medical and surgical treatment options for polycystic liver disease.","volume":"52","author":"Drenth","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"jrv250004r85","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"jrv250004r86","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","article-title":"Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.","volume":"145","author":"Gevers","year":"2013","journal-title":"Gastroenterology"},{"issue":"9","key":"jrv250004r87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257606","article-title":"Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials.","volume":"16","author":"Suwabe","year":"2021","journal-title":"PLoS One"},{"issue":"9378","key":"jrv250004r88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(03)13860-3","article-title":"Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment.","volume":"362","author":"Wiebers","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"jrv250004r89","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.","volume":"35","author":"Messchendorp","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"jrv250004r90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109698","article-title":"Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.","volume":"73","author":"Kashyap","year":"2020","journal-title":"Cell Signal"},{"issue":"9","key":"jrv250004r91","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/LVT.0000000000000414","article-title":"Policy Corner: polycystic liver disease MELD exception update.","volume":"30","author":"Mehta","year":"2024","journal-title":"Liver Transpl"},{"issue":"1","key":"jrv250004r92","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12876-021-01703-x","article-title":"Liver transplantation in adult polycystic liver disease: the Ontario experience.","volume":"21","author":"Alsager","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"jrv250004r93","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1111\/liv.14986","article-title":"Estrogens in polycystic liver disease: a target for future therapies?","volume":"41","author":"Aapkes","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"jrv250004r94","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2215\/CJN.08660621","article-title":"Volume progression and imaging classification of polycystic liver in early autosomal dominant polycystic kidney disease.","volume":"17","author":"Bae","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"jrv250004r95","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1161\/STR.0000000000000070","article-title":"Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"46","author":"Thompson","year":"2015","journal-title":"Stroke"},{"issue":"3","key":"jrv250004r96","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/j.ajkd.2020.01.005","article-title":"Core outcome domains for trials in autosomal dominant polycystic kidney disease: an international delphi survey.","volume":"76","author":"Cho","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"jrv250004r97","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.xkme.2019.07.015","article-title":"Foam sclerotherapy for cyst volume reduction in autosomal dominant polycystic kidney disease: a prospective cohort study.","volume":"1","author":"Iliuta","year":"2019","journal-title":"Kidney Med"},{"issue":"1","key":"jrv250004r98","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12882-024-03484-3","article-title":"Mortality risk in patients with autosomal dominant polycystic kidney disease.","volume":"25","author":"Mladsi","year":"2024","journal-title":"BMC Nephrol"},{"issue":"8","key":"jrv250004r99","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2215\/CJN.14691218","article-title":"Presymptomatic screening for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.","volume":"14","author":"Sanchis","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"jrv250004r100","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/archdischild-2015-310221","article-title":"Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis.","volume":"101","author":"Marlais","year":"2016","journal-title":"Arch Dis Child"},{"issue":"6","key":"jrv250004r101","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2215\/CJN.11401017","article-title":"Prevalence of hypertension in children with early-stage ADPKD.","volume":"13","author":"Massella","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"jrv250004r102","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/s41591-019-0534-z","article-title":"Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries.","volume":"25","author":"B\u00e9lisle-Pipon","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"jrv250004r103","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.akdh.2023.10.006","article-title":"Pregnancy in autosomal dominant polycystic kidney disease.","volume":"30","author":"Al Sayyab","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"5","key":"jrv250004r104","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1681\/ASN.V551178","article-title":"Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease.","volume":"5","author":"Chapman","year":"1994","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"jrv250004r105","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1681\/ASN.0000000000000253","article-title":"State of the science and ethical considerations for preimplantation genetic testing for monogenic cystic kidney diseases and ciliopathies.","volume":"35","author":"Thompson","year":"2024","journal-title":"J Am Soc Nephrol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2831904\/jama_chebib_2025_rv_250004_1746722684.29939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:03:42Z","timestamp":1747739022000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2831904"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":105,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,5,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.0310","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}